Dallah Healthcare Company provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia.
Share Price & News
How has Dallah Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4004 is not significantly more volatile than the rest of SA stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4004's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 4004 underperformed the SA Healthcare industry which returned 65% over the past year.
Return vs Market: 4004 exceeded the SA Market which returned 5.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Dallah Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StThe three-year decline in earnings for Dallah Healthcare TADAWUL:4004) isn't encouraging, but shareholders are still up 78% over that period
1 month ago | Simply Wall StDallah Healthcare Company's (TADAWUL:4004) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?
2 months ago | Simply Wall StDallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Dallah Healthcare Fundamentals Summary
|4004 fundamental statistics|
Is 4004 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4004 income statement (TTM)|
|Cost of Revenue||ر.س1.13b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.94|
|Net Profit Margin||9.82%|
How did 4004 perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Is Dallah Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 4004 (SAR71.7) is trading above our estimate of fair value (SAR43.06)
Significantly Below Fair Value: 4004 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 4004 is good value based on its PE Ratio (37.7x) compared to the SA Healthcare industry average (40.9x).
PE vs Market: 4004 is poor value based on its PE Ratio (37.7x) compared to the SA market (31x).
Price to Earnings Growth Ratio
PEG Ratio: 4004 is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: 4004 is overvalued based on its PB Ratio (3.5x) compared to the SA Healthcare industry average (2.8x).
How is Dallah Healthcare forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4004's forecast earnings growth (19.9% per year) is above the savings rate (8.8%).
Earnings vs Market: 4004's earnings (19.9% per year) are forecast to grow faster than the SA market (5.9% per year).
High Growth Earnings: 4004's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4004's revenue (10% per year) is forecast to grow faster than the SA market (3.1% per year).
High Growth Revenue: 4004's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4004's Return on Equity is forecast to be low in 3 years time (16.5%).
How has Dallah Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4004 has high quality earnings.
Growing Profit Margin: 4004's current net profit margins (9.8%) are lower than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: 4004's earnings have declined by 16.5% per year over the past 5 years.
Accelerating Growth: 4004's earnings growth over the past year (39.5%) exceeds its 5-year average (-16.5% per year).
Earnings vs Industry: 4004 earnings growth over the past year (39.5%) exceeded the Healthcare industry 29.5%.
Return on Equity
High ROE: 4004's Return on Equity (9.3%) is considered low.
How is Dallah Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: 4004's short term assets (SAR1.1B) exceed its short term liabilities (SAR843.7M).
Long Term Liabilities: 4004's short term assets (SAR1.1B) do not cover its long term liabilities (SAR1.3B).
Debt to Equity History and Analysis
Debt Level: 4004's debt to equity ratio (75.3%) is considered high.
Reducing Debt: 4004's debt to equity ratio has increased from 32% to 75.3% over the past 5 years.
Debt Coverage: 4004's debt is well covered by operating cash flow (25%).
Interest Coverage: 4004's interest payments on its debt are well covered by EBIT (7.8x coverage).
What is Dallah Healthcare current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4004's dividend (1.05%) isn’t notable compared to the bottom 25% of dividend payers in the SA market (1.49%).
High Dividend: 4004's dividend (1.05%) is low compared to the top 25% of dividend payers in the SA market (4.05%).
Stability and Growth of Payments
Stable Dividend: 4004 is not paying a notable dividend for the SA market, therefore no need to check if payments are stable.
Growing Dividend: 4004 is not paying a notable dividend for the SA market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 4004 is not paying a notable dividend for the SA market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4004's dividend in 3 years as they are not forecast to pay a notable one for the SA market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ahmad bin Babaeer (63 yo)
Dr. Ahmad bin Saleh Babaeer serves as the Chief Executive Officer of Dallah Healthcare Company since April 2021. Dr. Babaeer served as General Manager of Dallah Hospital at Dallah Healthcare Holding Co. Dr...
Experienced Management: 4004's management team is considered experienced (4.7 years average tenure).
Experienced Board: 4004's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.
Dallah Healthcare Company's company bio, employee growth, exchange listings and data sources
- Name: Dallah Healthcare Company
- Ticker: 4004
- Exchange: SASE
- Founded: 1994
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: ر.س6.453b
- Shares outstanding: 90.00m
- Website: https://www.dallahhealth.com
- Dallah Healthcare Company
- King Fahed Road
- Saudi Arabia
Dallah Healthcare Company provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthc...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 15:19|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.